ASX · CSL.AX
CSL Limited
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
Loading market information…
ASX · CMB.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 01:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Cambium Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cambium Bio Limited’s next earnings report is currently expected on Mar 4, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cambium Bio Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
$10.56-$0.16 (-1.49%)
Kura Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.03% below the high.
$7.33-$0.16 (-2.14%)
Olema Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.78% below the high.
A$0.02A$0.00 (0.0%)
Immutep Limited’s quoted price sits in the lower half of its reported 52-week range, 95.11% below the high.
A$0.10A$0.00 (0.0%)
Caspin Resources Limited’s quoted price sits in the lower half of its reported 52-week range, 51.22% below the high.
A$0.20+A$0.02 (+8.11%)
Cavalier Resources Limited’s quoted price sits in the lower half of its reported 52-week range, 56.52% below the high.
A$0.02-A$0.00 (-6.25%)
Cazaly Resources Limited’s quoted price sits in the lower half of its reported 52-week range, 61.54% below the high.
$0.10$0.00 (0.0%)
Chimeric Therapeutics Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
